Patients with HER2-positive breast cancer respond considerably better to targeted treatments like pertuzumab and trastuzumab (Herceptin), which work by inhibiting the function of the HER2 protein (Sun et al., 2022[191]). This evidence concerns the gene ERBB2 and breast carcinoma.